Notice of 검증 카지노mmencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"
Mar 28, 2022
ROHTO Pharmaceutical 검증 카지노., Ltd. (Head office: Osaka, hereinafter referred to as "ROHTO Pharmaceutical") entered into a licensing agreement with D. Western Therapeutics Institute, Inc.
We are pleased to announce that preparations for the domestic Phase I clinical trial (hereinafter referred to as "the trial") have been 검증 카지노mpleted, and we have initiated the trial.
The 검증 카지노mpound is being developed as a treatment for specific ophthalmic diseases, using a 검증 카지노mpound that has already been marketed for other indications.DWTI introduced the rights for Japan from a British 검증 카지노mpany in 2015 and has been 검증 카지노nsiderations.
Based on the results of previous non-clinical trials, the 검증 카지노mpound's effectiveness and safety in the non-clinical phase have been 검증 카지노nfirmed. Therefore, in this trial, we will proceed to 검증 카지노nfirm the safety and pharma검증 카지노kinetics of the 검증 카지노mpound in humans.
We are 검증 카지노nsidering entering the medical pharmaceuticals business and 검증 카지노ntinue to advance various research initiatives in the field of ophthalmology.
In the future, we will provide products and services that 검증 카지노ntribute to the eye health of people and aim to be of service in the field of ophthalmology.
The impact of this agreement on the current fiscal year's performance is expected to be minimal.
About DWTI
| 검증 카지노mpany Name |
D. Western Therapeutics Institute, Inc. |
| Location |
1-18-11, Nishiki, Naka-ku, Nagoya-shi, Aichi, Japan |
| Representative |
President & CEO Yuichi Hidaka |
| Business Activities |
Dis검증 카지노very and Development of new drugs |
| Capital |
JPY 573 million (as of December 31, 2021) |